Nearly 42% of adults struggle with weight management, yet many delay GLP-1 therapy because they lack insurance coverage
Access for weight management specifically varies by province and insurance coverage, though many Canadians obtain prescriptions through telehealth services or by working with physicians who recognize obesity as a chronic disease requiring medical intervention
Advances in receptor de-orphanization, spatial transcriptomics, and functional screening may ultimately clarify irisins mechanism of action and unlock its translational potential
As you become comfortable with how to reconstitute Retatrutide, the process becomes second nature
Retatrutide is an injectable triple agonist that targets GIP (glucose-dependent insulinotropic polypeptide), GLP-1, and glucagon receptors (GCG receptors) simultaneously
Compounding pharmacies create these formulations as an alternative to brand-name products like Ozempic and Wegovy